From: Recent advances in systemic therapy for hepatocellular carcinoma
Antibody-drug conjugates | ||||
---|---|---|---|---|
ADCs | Payload | Target | Stage | Reference |
Anti-CD147 ILs-DOX | doxorubicin | CD147 | preclinical | [139] |
G7mAb-DOX | doxorubicin | CD24 | preclinical | [140] |
MetFab-DOX | doxorubicin | c-MET | preclinical | [141] |
IMMU-132 | SN-38 | Trop-2 | phase I/II | [142] |
hYP7-DC | duocarmycin SA | GPC3 | preclinical | [143] |
hYP7-PC | pyrrolobenzodiazepine | |||
CLDN6-DM1 | mertansine | CLDN6 | preclinical | [144] |
Bispecific T cell engagers | ||||
BiTEs | TAA | T cell receptor | Stage | Reference |
1H8/CD3 | EpCAM | CD3 | preclinical | [145] |
solitomab | EpCAM | CD3 | phase I | [146] |
ERY974 | GPC3 | CD3 | phase I | [147] |